Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8
Antibodies, Monoclonal
/ administration & dosage
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biomarkers, Tumor
CD8-Positive T-Lymphocytes
/ drug effects
Disease Progression
Female
Humans
Immunohistochemistry
Lymphocyte Count
Male
Neoadjuvant Therapy
Oropharyngeal Neoplasms
/ drug therapy
Quality of Life
Risk Factors
Treatment Outcome
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 07 2020
01 07 2020
Historique:
received:
11
12
2019
revised:
17
02
2020
accepted:
03
04
2020
pubmed:
10
4
2020
medline:
15
9
2021
entrez:
10
4
2020
Statut:
ppublish
Résumé
In oropharyngeal squamous cell carcinoma (OPC), high CD8 Patients with newly diagnosed stage II-IVA OPC or locoregionally recurrent OPC amenable to resection were included. Patients were randomized to two cycles of durvalumab or durvalumab + tremelimumab before surgery. The primary endpoint was change between baseline and resection specimen in CD8 Of 28 eligible patients (14/arm), 20 (71%) had newly diagnosed OPC, and 24 (86%) were p16-positive. The posttreatment to pretreatment median CD8 Durvalumab + tremelimumab did not increase CD8
Identifiants
pubmed: 32269052
pii: 1078-0432.CCR-19-3977
doi: 10.1158/1078-0432.CCR-19-3977
pmc: PMC8362306
mid: NIHMS1718757
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Biomarkers, Tumor
0
durvalumab
28X28X9OKV
tremelimumab
QEN1X95CIX
Banques de données
ClinicalTrials.gov
['NCT03144778']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3211-3219Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189867
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Cancer Discov. 2016 Dec;6(12):1382-1399
pubmed: 27663893
Head Neck. 2005 Oct;27(10):843-50
pubmed: 16161069
Oral Oncol. 2016 Nov;62:101-108
pubmed: 27865361
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80
pubmed: 20160101
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
J Clin Invest. 2014 May;124(5):2246-59
pubmed: 24667641
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Laryngoscope. 2010 Sep;120(9):1749-55
pubmed: 20717944
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
N Engl J Med. 2015 Sep 24;373(13):1270-1
pubmed: 26398076
Oncotarget. 2017 Jul 6;8(46):80443-80452
pubmed: 29113315
Oral Oncol. 2017 Apr;67:160-166
pubmed: 28351571
Cancers Head Neck. 2016 Jul 4;1:7
pubmed: 31093337
Eur J Cancer. 2019 Jan;107:142-152
pubmed: 30576970
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
J Clin Oncol. 2014 Dec 1;32(34):3858-66
pubmed: 25366680
Am Soc Clin Oncol Educ Book. 2018 May 23;38:505-514
pubmed: 30231400
N Engl J Med. 2007 Oct 25;357(17):1705-15
pubmed: 17960013
PLoS One. 2012;7(6):e38711
pubmed: 22701698
Cancer Immunol Res. 2018 Mar;6(3):295-304
pubmed: 29378694
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Cancer Discov. 2016 Aug;6(8):827-37
pubmed: 27301722
J Clin Oncol. 2003 Jan 15;21(2):327-33
pubmed: 12525526
JAMA Oncol. 2016 Apr;2(4):508-16
pubmed: 26720612
Cancer. 2009 Dec 15;115(24):5723-33
pubmed: 19760612
J Clin Oncol. 2014 Oct 20;32(30):3365-73
pubmed: 24958820
JAMA Oncol. 2019 Jan 1;5(1):67-73
pubmed: 30267032
Head Neck. 2007 Oct;29(10):923-31
pubmed: 17358040
JAMA Oncol. 2019 Feb 1;5(2):195-203
pubmed: 30383184
J Clin Oncol. 2008 Jul 20;26(21):3582-9
pubmed: 18559875
Future Sci OA. 2016 Jan 07;2(1):FSO88
pubmed: 28031938
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
J Clin Oncol. 2017 May 10;35(14):1542-1549
pubmed: 28328302
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
Nat Med. 2018 Nov;24(11):1655-1661
pubmed: 30297911
J Clin Oncol. 2013 Feb 20;31(6):744-51
pubmed: 23129742
J Immunother Cancer. 2014 Feb 18;2:3
pubmed: 24829760